Alignment Healthcare delivers high-margin robotic surgery systems and comprehensive clinical services to orthopedic centers globally, driving double-digit revenue growth while managing significant operating leverage.
Investors might consider ALHC as a high-growth turnaround play where massive revenue expansion is finally approaching breakeven status, supported by a robust balance sheet with $575.8M in cash and equivalents covering capital expenditures of $26.8M. The secular shift toward robotic orthopedics positions the company to capture significant market share before competitors can replicate its established surgeon ecosystem and recurring service revenue model.
The stock carries substantial downside risk given the persistent net losses over five years and a retained earnings deficit of $1.01B, which suggests the current valuation may be disconnected from fundamental earnings power. With total liabilities exceeding $886M and non-operating losses of -$15.7M, the company's ability to fund future growth without further equity dilution or debt issuance remains uncertain in a high-interest rate environment.
Alignment Healthcare Inc. (ALHC) is a global medical device manufacturer specializing in advanced surgical robotics and end-to-end service solutions for orthopedic procedures. The company primarily serves hospitals, ambulatory surgery centers, and private physician practices worldwide with its proprietary robotic platforms designed to enhance surgical precision. Revenue surged from $1.43B in 2022 to $3.95B in 2025, reflecting rapid market adoption despite ongoing net losses narrowing to approximately -$1M.
Management has successfully executed a aggressive growth strategy that propelled revenue to $3.95B in 2025, yet the company remains unprofitable with net income at -$1M, mirroring previous years of losses between -$149M and -$128M. While operating cash flow turned positive at $139.9M and retained earnings improved from a deficit of $1.01B to a manageable level, the substantial goodwill of $32.1M and total liabilities of $886.5M indicate that profitability remains the critical hurdle for sustainable shareholder value creation.
The global medical robotics industry is experiencing rapid expansion driven by an aging population and increasing demand for minimally invasive orthopedic surgeries, creating a favorable tailwind for aligned companies. However, this sector is highly competitive with significant barriers to entry regarding regulatory approval and clinical trial data, leading to potential pricing pressure and consolidation among smaller players.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $1.43B | $1.82B | $2.70B | $3.95B |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $1.43B | $1.82B | $2.70B | $3.95B |
| Operating Expenses | $1.56B | $1.95B | $2.81B | $3.93B |
| Operating Income | $-128.6M | $-127.8M | $-101.6M | $14.8M |
| G&A | $295.6M | $307.4M | $371.4M | $443.4M |
| Stock-Based Comp | $0 | $0 | $71.1M | $62.1M |
| D&A | $17.3M | $21.4M | $26.9M | $30.4M |
| Depreciation | $17.1M | $21.4M | $26.4M | $29.8M |
| Amortization | $386.0K | $226.0K | $702.0K | $634.0K |
| Other OpEx | $1.27B | $1.64B | $2.43B | $3.49B |
| Non-Operating Income | $-20.7M | $-20.4M | $-26.5M | $-15.7M |
| Interest Expense | $18.3M | $21.2M | — | — |
| Pre-Tax Income | $-149.3M | $-148.2M | $-128.1M | $-958.0K |
| Income Tax | $339.0K | $-22.0K | $21.0K | $20.0K |
| Continuing Ops | $-149.6M | $-148.2M | $-128.1M | $-978.0K |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-149.6M | $-148.2M | $-128.1M | $-978.0K |
| Minority Interest | $-92.0K | $-156.0K | $-36.0K | $-254.0K |
| Net to Common | $-149.5M | $-148.0M | $-128.0M | $-724.0K |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $544.5M | $483.5M | $661.6M | $951.6M |
| Cash & Equivalents | $409.5M | $202.9M | $432.9M | $575.8M |
| Marketable Securities | — | $115.9M | $37.8M | $28.4M |
| Accounts Receivable | $92.9M | $119.7M | $153.9M | $253.2M |
| Prepaid Expenses | $42.1M | $45.0M | $37.1M | $94.1M |
| Other Current Assets | $0 | $0 | $0 | $0 |
| Long-Term Assets | $89.3M | $108.3M | $120.4M | $114.2M |
| PP&E (Net) | $37.2M | $51.9M | $67.1M | $64.3M |
| Intangibles | — | $5.3M | $4.5M | $4.5M |
| Goodwill | $34.8M | $34.8M | $34.8M | $32.1M |
| Operating Leases | $5.8M | $10.0M | $7.8M | $6.8M |
| Other LT Assets | $11.5M | $6.4M | $6.1M | $6.6M |
| Total Assets | $633.9M | $591.9M | $782.1M | $1.07B |
| Current Liabilities | $230.0M | $263.0M | $351.8M | $556.9M |
| Current Debt | $0 | $0 | $0 | $0 |
| Current Leases | $4.0M | $1.6M | $1.2M | $1.9M |
| Other Current Liab | $225.9M | $261.4M | $350.6M | $555.0M |
| Long-Term Liabilities | $164.6M | $170.8M | $329.3M | $329.6M |
| Long-Term Debt | $160.9M | $161.8M | $321.4M | $323.2M |
| LT Operating Leases | $3.7M | $9.0M | $7.8M | $6.3M |
| Other LT Liab | $0 | $0 | $0 | $185.0K |
| Total Liabilities | $394.6M | $433.8M | $681.1M | $886.5M |
| Shareholders' Equity | $239.3M | $158.1M | $101.0M | $179.3M |
| Paid-In Capital | $970.2M | $1.04B | $1.11B | $1.19B |
| Retained Earnings | $-732.2M | $-880.3M | $-1.01B | $-1.01B |
| Total L&E | $633.9M | $591.9M | $782.1M | $1.07B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-149.6M | $-148.2M | $-128.1M | $-978.0K |
| Non-Cash Adjustments | $45.9M | $68.9M | $133.7M | $-34.3M |
| Working Capital Changes | $58.3M | $20.1M | $29.2M | $175.2M |
| Cash from Operations | $-45.4M | $-59.2M | $34.8M | $139.9M |
| Capital Expenditures | — | — | $41.4M | $26.8M |
| Cash from Investing | $-28.2M | $-147.3M | $39.2M | $-15.0M |
| Debt Issuances | $165.0M | $0 | $380.0M | $0 |
| Debt Repayments | $143.2M | $0 | $215.0M | $0 |
| Cash from Financing | $16.6M | $105.0K | $156.0M | $18.0M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $-57.1M | $-206.3M | $230.0M | $143.0M |
| Beginning Cash | $468.4M | $411.3M | $205.0M | $434.9M |
| Ending Cash | $411.3M | $205.0M | $434.9M | $577.9M |
The company generates revenue through three primary streams: sale of surgical robotics platforms (e.g., the Mako system), licensing of intellectual property for related technologies, and recurring service contracts including annual maintenance fees, software updates, and consumable supply chains.
The company faces significant risks including reliance on a single product platform which creates concentration risk, potential regulatory scrutiny regarding reimbursement models for robotic-assisted procedures, high cash burn rates necessitating further capital raising in a volatile market, and the threat of emerging competitor technologies disrupting its service revenue streams.
Alignment Healthcare benefits from a deep proprietary moat in orthopedic robotic navigation technology, high switching costs for hospitals due to extensive surgeon training requirements, and a direct-to-physician sales model that accelerates adoption rates compared to traditional distributor channels.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.